Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 254 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Wet (Neovascular / Exudative) Macular Degeneration Overview 10
Therapeutics Development 11
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 24
Aciont Inc. 24
Allergan Plc 25
Amakem NV 26
Apellis Pharmaceuticals, Inc. 27
Apexigen, Inc. 28
Applied Genetic Technologies Corporation 29
Avalanche Biotechnologies, Inc. 30
Benitec Biopharma Limited 31
BIOCAD 32
Boehringer Ingelheim GmbH 33
Charlesson LLC. 34
Chong Kun Dang Pharmaceutical Corp. 35
Circadian Technologies Limited 36
Clanotech AB 37
Clearside BioMedical, Inc. 38
Coherus BioSciences, Inc. 39
Daiichi Sankyo Company, Limited 40
Delenex Therapeutics AG 41
Eleven Biotherapeutics Inc. 42
Exonate Limited 43
F. Hoffmann-La Roche Ltd. 44
Formycon AG 45
GTx, Inc. 46
iCo Therapeutics Inc. 47
Icon Bioscience, Inc. 48
Kala Pharmaceuticals, Inc. 49
Kodiak Sciences, Inc. 50
Mabion SA 51
Mitotech S.A. 52
Neurotech Pharmaceuticals, Inc. 53
Ocular Therapeutix, Inc. 54
Ohr Pharmaceutical Inc. 55
Ophthotech Corp. 56
Oxford BioMedica Plc 57
PanOptica, Inc. 58
Pfenex Inc. 59
Pfizer Inc. 60
pSivida Corp. 61
Quark Pharmaceuticals, Inc. 62
Regeneron Pharmaceuticals, Inc. 63
RegenxBio Inc. 64
RXi Pharmaceuticals Corporation 65
Santen Pharmaceutical Co., Ltd. 66
Sanwa Kagaku Kenkyusho Co., Ltd. 67
TRACON Pharmaceuticals, Inc. 68
TWi Pharmaceuticals, Inc. 69
Tyrogenex, Inc. 70
Xbrane Biopharma AB 71
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 72
Assessment by Monotherapy Products 72
Assessment by Combination Products 73
Assessment by Target 74
Assessment by Mechanism of Action 77
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
(aflibercept + nesvacumab) - Drug Profile 84
(aflibercept + rinucumab) - Drug Profile 85
abicipar pegol - Drug Profile 86
AC-301 - Drug Profile 89
ACX-107 - Drug Profile 90
aflibercept - Drug Profile 91
aflibercept biosimilar - Drug Profile 94
AGN-151200 - Drug Profile 95
ALG-1001 - Drug Profile 96
AMA-0428 - Drug Profile 98
APL-2 - Drug Profile 99
APX-003 - Drug Profile 101
APX-3330 - Drug Profile 102
AVA-101 - Drug Profile 104
AVA-201 - Drug Profile 106
avacincaptad pegol sodium - Drug Profile 107
AXT-108 - Drug Profile 109
bertilimumab - Drug Profile 110
Beta-LGND2 - Drug Profile 112
bevacizumab biosimilar - Drug Profile 114
BI-144807 - Drug Profile 115
brolucizumab - Drug Profile 116
C-16Y - Drug Profile 118
CLT-005 - Drug Profile 119
CLT-28643 - Drug Profile 120
cyclosporine - Drug Profile 121
DE-120 - Drug Profile 122
DLX-1008 - Drug Profile 123
DNX-214 - Drug Profile 124
Doxarubicin Pegylated - Drug Profile 125
Drug for Age Related Macular Degeneration - Drug Profile 126
Drug for Wet AMD and Dry AMD - Drug Profile 127
DS-7080 - Drug Profile 128
ENV-1305 - Drug Profile 129
ENV-705 - Drug Profile 130
GB-101 - Drug Profile 131
GB-102 - Drug Profile 132
Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 133
K-106 - Drug Profile 134
KSI-201 - Drug Profile 135
LHA-510 - Drug Profile 136
LMG-324 - Drug Profile 137
Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration - Drug Profile 138
nesvacumab - Drug Profile 139
NT-503 - Drug Profile 141
NT-506 - Drug Profile 142
OCU-200 - Drug Profile 143
OLX-301 - Drug Profile 144
ONL-1204 - Drug Profile 145
OXB-201 - Drug Profile 146
PAN-90806 - Drug Profile 147
pegpleranib sodium - Drug Profile 149
PF-05206388 - Drug Profile 151
PF-655 - Drug Profile 152
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 155
Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 157
ranibizumab - Drug Profile 158
ranibizumab biosimilar - Drug Profile 162
ranibizumab biosimilar - Drug Profile 163
ranibizumab biosimilar - Drug Profile 164
ranibizumab biosimilar - Drug Profile 166
ranibizumab biosimilar - Drug Profile 167
ranibizumab biosimilar - Drug Profile 168
ranibizumab biosimilar - Drug Profile 169
Recombinant Protein for Age Related Macular Degeneration - Drug Profile 170
Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 171
RG-7716 - Drug Profile 172
RGX-314 - Drug Profile 173
RXI-109 - Drug Profile 174
SK-1011 - Drug Profile 176
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 177
Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile 178
SPHINX-31 - Drug Profile 180
squalamine lactate - Drug Profile 181
Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 184
TRC-105 - Drug Profile 185
triamcinolone acetonide - Drug Profile 188
TT-211 - Drug Profile 189
TT-231 - Drug Profile 190
VGX-300 - Drug Profile 191
X-82 - Drug Profile 193
Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 195
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 235
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 235
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 238
Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 239
Featured News & Press Releases 239
Appendix 247
Methodology 247
Coverage 247
Secondary Research 247
Primary Research 247
Expert Panel Validation 247
Contact Us 247
Disclaimer 248

List of Tables
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Development by Companies, H1 2016 (Contd..3) 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Products under Development by Companies, H1 2016 25
Products under Development by Companies, H1 2016 (Contd..1) 26
Products under Development by Companies, H1 2016 (Contd..2) 27
Products under Development by Companies, H1 2016 (Contd..3) 28
Products under Development by Companies, H1 2016 (Contd..4) 29
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H1 2016 30
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H1 2016 31
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H1 2016 32
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 33
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H1 2016 34
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2016 35
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H1 2016 36
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2016 37
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H1 2016 38
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2016 39
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H1 2016 40
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 41
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H1 2016 42
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H1 2016 43
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H1 2016 44
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H1 2016 45
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Delenex Therapeutics AG, H1 2016 47
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H1 2016 48
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H1 2016 49
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H1 2016 51
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H1 2016 52
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2016 53
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2016 54
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 55
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences, Inc., H1 2016 56
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H1 2016 57
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H1 2016 58
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016 59
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H1 2016 60
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H1 2016 61
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2016 62
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H1 2016 63
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H1 2016 64
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H1 2016 65
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H1 2016 66
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H1 2016 67
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 68
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 69
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H1 2016 70
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 71
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 72
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 73
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 74
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 75
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H1 2016 76
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H1 2016 77
Assessment by Monotherapy Products, H1 2016 78
Assessment by Combination Products, H1 2016 79
Number of Products by Stage and Target, H1 2016 81
Number of Products by Stage and Mechanism of Action, H1 2016 84
Number of Products by Stage and Route of Administration, H1 2016 87
Number of Products by Stage and Molecule Type, H1 2016 89
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2016 201
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H1 2016 241
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H1 2016 242
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H1 2016 243
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H1 2016 244